Boehringer Pledges Another €30m To Tackle AMR
Launches JV With Evotec and BioMérieux
Executive Summary
The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.
You may also be interested in...
Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
Plotting The Path For Pharma To Maintain New-Found Trust
Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.